Clinical trial NCT00003726: Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
Official title: A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Lung Cancer
Keywords: extensive stage small cell lung cancer
recurrent small cell lung cancer
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-05-03
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer.

PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in treating patients with recurrent or advanced small cell lung cancer.

Detailed description: OBJECTIVES: I. Determine the dose, safety, and antitumor response rate of lepirudin in patients with recurrent or extensive stage small cell lung cancer previously treated with chemotherapy.

OUTLINE: This is a dose escalation (in individual patients) study. Patients receive dose escalated lepirudin subcutaneously once or twice a day for 3-4 days. Dose escalation continues in each patient until aPTT prolongation occurs or the maximum dose level is reached. The patient then continues treatment on the maximum tolerated dose. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 18-24 months.

Eligibility criteria: DISEASE CHARACTERISTICS:

1. Pathologically confirmed recurrent or extensive stage small cell lung cancer.
2. Received at least one prior chemotherapy regimen
3. Measurable or evaluable disease that has not been irradiated
4. No pleural effusions, bone metastases, brain metastases, elevated serum enzymes, or radionuclide scans as the sole indicator lesion
5. Brain metastases allowed if patients received cranial irradiation and have no clinical evidence of brain metastases

PATIENT CHARACTERISTICS:

1. Age: Not specified
2. Performance status: Karnofsky 60-100%
3. Life expectancy: Not specified
4. Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
5. Hepatic: Bilirubin no greater than 2.0 mg/dL PT and aPTT normal
6. Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min
7. Cardiovascular: No unstable heart rhythm No unstable angina No clinical evidence of congestive heart failure No prior cerebrovascular accident or stroke No uncontrolled or severe hypertension
8. Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
9. At least 6 weeks since any signs or symptoms of bleeding No history of bleeding disorder
10. No bacterial endocarditis or other active infection

PRIOR CONCURRENT THERAPY:

1. Biologic therapy: Not specified
2. Chemotherapy: At least 3 weeks since prior chemotherapy
3. Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy
4. Surgery: At least 6 weeks since major surgery, trauma, or needle biopsy of any organ
5. Other: No concurrent anticoagulant or platelet inhibitor therapy

Primary outcomes:
measure: Dose, Safety and Antitumor Response Rate of Administering Recombinant Desulfato Hirudin, Elpirudin to Previously Treated Patients With Extensive or Recurrent Small Cell Lung Cancer
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Norris Cotton Cancer Center
state: New Hampshire
Study officials:
affiliation: Norris Cotton Cancer Center
name: James R. Rigas, MD
role: STUDY_CHAIR
References: